Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
- no estimate extracted2 studies · 691 participantsLow